Pharmaceutical Industry Information Portal

HomeTagsPromomed Group

All posts by tag

Promomed Group

The Medsintez Plant has launched a full-cycle production of hypoglycemic drugs for treating type II diabetes mellitus

In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease.

PROMOMED obtained permission to produce drug product for diabetes mellitus Kvinsenta with semaglutide

The Russian government has published an order authorizing PROMOMED GROUP to use inventions protected by patents of the Danish company Novo Nordisk related to a drug product with semaglutide for the treatment of diabetes mellitus.

New product from Promomed Group for protection, ensure the functioning and repair of the nervous system cells

Promomed Group has registered a new drug Brainmax®, reaffirming its commitment to the strategy of launching innovative, knowledge-based products. The technology developed by the...

The new direct acting anticoagulant in the anticovid portfolio of Promomed Group

Promomed Group received marketing authorization certificate for a medicinal product with nadroparin calcium as active ingredient. Nadroparin is a low molecular weight heparin. It...

Russian Ministry of Health included injectable Areplivir® in the guidelines for the treatment of COVID-19

The Ministry of Health of the Russian Federation has included the injectable form of the direct-acting antiviral drug Areplivir® (favipiravir) in the updated, fourteenth, version...

Biokhimik JSC of Promomed Group and Mordovia State University agreed on further cooperation

At the meeting of the management of Biokhimik JSC with Acting Rector of the Ogarev Mordovia State University Dmitry Glushko and the scientific community...
spot_img

Expert Articles

spot_img